Clinical Trials
8 trialsNCT03387917 2024-12-02
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
Phase 1 Terminated
NCT00819221 2022-08-30
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AstraZeneca
Phase 1 Terminated
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT01214668 2019-01-04
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01702129 2014-09-09
Anti-EGFR Immunoliposomes in Solid Tumors
University Hospital, Basel, Switzerland
Phase 1 Completed
NCT00500422 2013-02-13
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01148628 2011-09-13
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
Southern Europe New Drug Organization
Phase 1 Unknown
NCT00886028 2009-04-22
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
National Institute of Cancerología
Phase 2 Unknown